On Demand Pharmaceuticals, Inc.
Developer and operator of a distributed, modular pharmaceutical production platform designed to produce sterile injectable medicines and small-scale APIs at or near the point of care. Offers on-site and regional production services built to meet 503A/503B compounding requirements, with cGMP-ready facilities, software-driven manufacturing workflows, and AI/ML-enabled supply chain analytics to mitigate drug shortages and improve supply-chain resilience.
Industries
N/A
Nr. of Employees
small (1-50)
On Demand Pharmaceuticals, Inc.
On Demand Pharmaceuticals, Inc., 1550 East Gude Drive, Rockville, MD 20850, United States
Products
Modular on-site medicine production platform (Pharmacy on Demand)
A modular production platform designed to produce APIs and final formulated sterile injectables at or near the point of care, integrating miniaturized continuous manufacturing, purification modules, and software-driven workflows.
Modular on-site medicine production platform (Pharmacy on Demand)
A modular production platform designed to produce APIs and final formulated sterile injectables at or near the point of care, integrating miniaturized continuous manufacturing, purification modules, and software-driven workflows.
Services
Patient-specific and anticipatory sterile compounding services designed to address immediate local drug shortages under 503A frameworks.
cGMP-compliant production and repackaging service for larger volume needs, including access to expanded formulary updates and terminal sterilization.
Predictive analytics and market intelligence to identify at-risk medicines and optimize raw-material sourcing and production planning.
Rapidly deployable production capability to support medicine supply during disasters, pandemics, and other surge events.
Regional raw material and small-batch API synthesis integrated with repackaging and finished-dose manufacturing to supply distributed nodes.
Patient-specific and anticipatory sterile compounding services designed to address immediate local drug shortages under 503A frameworks.
cGMP-compliant production and repackaging service for larger volume needs, including access to expanded formulary updates and terminal sterilization.
Predictive analytics and market intelligence to identify at-risk medicines and optimize raw-material sourcing and production planning.
Rapidly deployable production capability to support medicine supply during disasters, pandemics, and other surge events.
Regional raw material and small-batch API synthesis integrated with repackaging and finished-dose manufacturing to supply distributed nodes.
Expertise Areas
- Distributed pharmaceutical manufacturing
- 503A/503B compounding and sterile injectable production
- cGMP compliance and regulatory submissions
- AI/ML-driven supply chain analytics and shortage mitigation
Key Technologies
- Miniaturized continuous manufacturing
- Flow chemistry
- AI/ML-driven supply chain analytics
- Modular cleanroom and modular manufacturing units
News & Updates
Senior officials from the U.S. Department of Health and Human Services visited the company's Centralized Production and Repackaging (CPR) facility in Rockville, Maryland to evaluate domestic pharmaceutical manufacturing capabilities.
Announcement of qualification of equipment and capabilities supporting cGMP operations in a centralized raw-material production site and a modular point-of-care site.
Two-day meeting with state delegations, funding partners, and healthcare partners to discuss distributed production, regulatory compliance, and pilot outcomes at North Mississippi Health Services.
Pilot Pharmacy on Demand operation produced approximately 12,000 prefilled syringes across a fixed formulary of shortage-listed medications under 503A guidelines; granted authority to compound across an unrestricted formulary following inspection.
Project sponsored by a defense research office advanced to include a Drug Master File (DMF) filing and an Abbreviated New Drug Application (ANDA) submission to FDA in support of distributed manufacturing demonstration.
Senior officials from the U.S. Department of Health and Human Services visited the company's Centralized Production and Repackaging (CPR) facility in Rockville, Maryland to evaluate domestic pharmaceutical manufacturing capabilities.
Announcement of qualification of equipment and capabilities supporting cGMP operations in a centralized raw-material production site and a modular point-of-care site.
Two-day meeting with state delegations, funding partners, and healthcare partners to discuss distributed production, regulatory compliance, and pilot outcomes at North Mississippi Health Services.
Pilot Pharmacy on Demand operation produced approximately 12,000 prefilled syringes across a fixed formulary of shortage-listed medications under 503A guidelines; granted authority to compound across an unrestricted formulary following inspection.
Project sponsored by a defense research office advanced to include a Drug Master File (DMF) filing and an Abbreviated New Drug Application (ANDA) submission to FDA in support of distributed manufacturing demonstration.